← Back to Search

Mucolytic Agent

Dornase Alpha for the Treatment of COVID-19

Phase 2
Waitlist Available
Led By Ercument Ovalı, MD
Research Sponsored by Acibadem University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

In this study, the effectiveness of the Dornase Alpha treatment, which is known to reduce the viscosity of respiratory secretions, will be investigated in new diagnosed and severe COVID-19 patients separately.

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Response
Secondary study objectives
Survival

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Patient Group Monitored by Mechanical Ventilation (n=30)Experimental Treatment1 Intervention
I. Dornase Alpha treated group (n=15) ii. Control group (n=15)
Group II: Newly Diagnosed Patient Group (n=30)Experimental Treatment1 Intervention
I. Dornase Alpha treated group (n=15) ii. Control group (n=15)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dornase alfa
FDA approved

Find a Location

Who is running the clinical trial?

Acibadem UniversityLead Sponsor
164 Previous Clinical Trials
43,928 Total Patients Enrolled
The Scientific and Technological Research Council of TurkeyOTHER
176 Previous Clinical Trials
23,624 Total Patients Enrolled
Ercument Ovalı, MDPrincipal InvestigatorAcıbadem Labcell Cellular Therapy Laboratories
~11 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top